The landscape of breast cancer care is undergoing a seismic shift. As clinical evidence mounts regarding the potential for overtreatment in patients with hormone receptor-positive (HR+), HER2-negative breast cancer, the medical community is intensifying its search for more precise, less invasive therapeutic strategies. At the heart of this transition is Atossa Therapeutics, a clinical-stage biopharmaceutical company betting on a modernized approach to one of the oldest stalwarts of oncology: tamoxifen.
By focusing on endoxifen—the active metabolite of tamoxifen—Atossa aims to bypass the physiological limitations that have historically hindered the effectiveness of traditional endocrine therapy. This development coincides with a broader industry movement toward "de-escalation," where the goal is to spare patients the grueling systemic effects of chemotherapy without compromising long-term survival outcomes.
The Foundation: Tamoxifen’s Legacy and Its Metabolic Limitations
Since its FDA approval in 1977, tamoxifen has been a cornerstone of breast cancer treatment. As the first targeted therapy for the disease, it revolutionized adjuvant care, consistently demonstrating an ability to reduce the risk of recurrence by approximately 32% within the first four years of treatment. For decades, it has served as the standard-of-care for preventing recurrence in patients with estrogen receptor-positive breast cancer.
However, the efficacy of tamoxifen is inextricably linked to the patient’s liver function. Tamoxifen is a prodrug, meaning it must be metabolized by the liver into its active forms to exert its therapeutic effect. Specifically, the liver processes the drug into roughly 22 different metabolites, with endoxifen being the most potent.
"In order for tamoxifen to work, it requires heavy-duty work by the liver," explains Janet Rea, Senior Vice President of R&D at Atossa Therapeutics. "Some metabolites are more active than others, and that’s a significant metabolic burden on the liver."
This metabolic dependency creates a major clinical challenge: genetic variability. Patients possess different levels of the CYP2D6 enzyme, which is responsible for converting tamoxifen into endoxifen. Consequently, patients classified as "poor metabolizers" may never achieve therapeutic levels of the drug, rendering their treatment less effective. Conversely, "ultra-metabolizers" might process the drug too quickly, potentially leading to varied therapeutic responses.
Chronology: From Discovery to Precision Medicine
The realization that endoxifen is the primary driver of tamoxifen’s efficacy dates back to the early 2000s. While researchers identified this early on, translating this scientific insight into a viable pharmaceutical product proved to be a formidable task.
The primary hurdle was biological: the active form of endoxifen is notoriously unstable when exposed to stomach acid. For years, this prevented the development of an oral formulation that could reach the bloodstream intact. Atossa Therapeutics eventually overcame this through the application of advanced drug delivery technology—specifically, an enteric-coated capsule designed to bypass the harsh environment of the stomach and dissolve predictably in the gastrointestinal tract.
This technical milestone paved the way for clinical investigation. In a notable Phase 2 sub-study within the prestigious I-SPY 2 trial, 20 women with stage II/III ER-positive, HER2-negative breast cancer were treated with low-dose oral endoxifen prior to surgery. The results were compelling: a median reduction in Ki67 (a marker of tumor cell proliferation) from 10.5% at baseline to 5% by the third week. Furthermore, MRI scans confirmed substantial tumor shrinkage, and the treatment demonstrated a favorable safety profile.
The Case for De-escalation: Insights from the OPTIMA Trial
The urgency behind Atossa’s development of endoxifen is fueled by emerging data suggesting that many patients currently receiving chemotherapy could potentially avoid it.
The Phase 3 OPTIMA trial, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, provided a significant boost to this argument. The data revealed that 68% of high-risk patients were able to forgo chemotherapy without sacrificing survival. Among those who skipped chemo, the five-year invasive breast cancer-free survival rate was 93.7%, compared to 94.9% for those who underwent standard chemotherapy—a statistically non-inferior result.
Despite these promising findings, experts remain cautious. Robert Stein, the trial’s chief investigator, noted that because the study recruited patients over nearly nine years, fewer than 40% of participants had reached the five-year follow-up mark at the time of the presentation. This has resulted in wider-than-desired statistical confidence intervals. Nevertheless, the trend is clear: the oncology field is moving toward a more nuanced, biomarker-driven approach to deciding who truly needs the toxicity of chemotherapy.
Strategic Implications: Where Endoxifen Fits
Atossa envisions endoxifen playing multiple roles in the treatment paradigm, primarily as a neoadjuvant (pre-surgery) or adjuvant (post-surgery) therapy.
Pre-Surgical Potential
Rea suggests that endoxifen could be used to shrink tumors before surgery, potentially reducing the need for aggressive procedures or extensive reconstruction. "If you can shrink the tumor, you may need less invasive surgery," she explains. Furthermore, there is the optimistic possibility that, for some patients, endoxifen treatment could reduce the tumor to a state where "watchful waiting" becomes a viable alternative to immediate surgical intervention.
Expanding Access
The potential for endoxifen extends beyond standard female patients. It could represent a crucial option for male breast cancer patients, whose treatment options are currently limited. Additionally, it offers a lifeline to patients who cannot tolerate aromatase inhibitors—another common endocrine therapy—due to pre-existing conditions like severe osteoporosis.
The Competitive Landscape: SERMs and SERDs
Atossa is not the only company aiming to disrupt the endocrine therapy market. The emergence of next-generation Selective Estrogen Receptor Modulators (SERMs) and Selective Estrogen Receptor Degraders (SERDs) has created a crowded, highly competitive field.
- Lasofoxifene: Licensed by LeonaBio from Sermonix Pharmaceuticals, this nonsteroidal SERM is currently in Phase 3 trials for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.
- Elacestrant (Orserdu): Approved by the FDA in 2023, this was the first oral SERD for patients with ESR1-mutated advanced or metastatic breast cancer who have progressed on at least one prior endocrine therapy.
- Giredestrant and Imlunestrant: Roche and Eli Lilly are aggressively pursuing the SERD space. While Roche’s giredestrant has seen mixed results—posting positive Phase 3 data in metastatic settings but missing a primary endpoint in a first-line metastatic trial—Lilly’s imlunestrant recently gained FDA approval for similar patient populations.
Future Outlook: A Biomarker-Driven Era
As the field moves toward a more personalized model of care, the definition of success in oncology is being rewritten. "One size doesn’t fit all when it comes to cancer therapy," Rea emphasizes. She believes that as researchers gain a deeper understanding of tumor dynamics—what drives their growth and what shuts them down—the industry will see an influx of therapies that target specific cellular attributes.
The regulatory environment is also evolving. According to Rea, the FDA is showing an increased willingness to consider biomarker-driven evidence as a legitimate basis for treatment decisions, including the decision to avoid chemotherapy. This represents a significant shift from the broad-spectrum treatment protocols of the past.
Within the next three to five years, it is expected that clinicians will have a significantly more robust "toolkit" of diagnostic tests and targeted therapies. By characterizing the specific biology of a tumor, doctors will be able to tailor treatment regimens that maximize efficacy while minimizing unnecessary harm to the patient.
In this context, Atossa’s focus on endoxifen is more than just a drug development project; it is a manifestation of a broader, necessary evolution in medicine. As data from ongoing trials matures and the industry refines its understanding of patient-specific responses, the goal of "precision oncology"—treating the right patient with the right drug at the right time—is steadily moving from a theoretical ideal to a clinical reality.
About the Author
